GlaxoSmithKline PLC (NYSE:GSK) is reporting third quarter financial results on Wednesday 28th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, GSK is expected to report 3Q20 income of $ 0.87 per share from revenue of $ 11672.30 million.
For the full year, analysts anticipate top line of $ 45035.90 million, while looking forward to income of $ 3.01 per share bottom line.
The Company Outlook
Full Year 2020 bottomline are predicted in a range of $ 1.56 ~ $ 1.60 per share
Click Here For More Historical Outlooks Of GlaxoSmithKline PLC
Previous Quarter Performance
GlaxoSmithKline PLC unveiled income for the second quarter of $ 0.24 per share, from the revenue of $ 9,459.00 million. The quarterly earnings contracted 69.62 percent while revenues declined 5.74 percent compared with the same quarter last year.
Street analysts expected GlaxoSmithKline PLC to report income of $ 0.51 per share on revenue of $ 9802.33 million for the second quarter. The bottom line results missed street analysts by $ 0.27 or 52.94 percent, at the same time, top line results fell short of analysts by $ 343.33 million or 3.5 percent.
Stock Performance
Shares of GlaxoSmithKline PLC traded up $ 0.13 or 0.37 percent on Tuesday, reaching $ 35.35 with volume of 6.65 million shares. GlaxoSmithKline PLC has traded high as $ 35.78 and has cracked $ 35.31 on the downward trend
According to the previous trading day, closing price of $ 35.35, representing a 12.06 % increase from the 52 week low of $ 31.43 and a 27.01 % decrease over the 52 week high of $ 48.25.
The company has a market capital of $ 88.33 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and dermatology.
